SID & GP took part in a Conference in honor of the EMA’s 25th Anniversary

The welcome remarks were delivered by Chair of the EMA’s Management Board Dr. Christa Wirthumer-Hoche, Deputy Executive Director Mr. Noël Wathion, European Commission’s Deputy Director-General for Health and Food Safety Ms. Sandra Gallina and Director-General of the Danish Medicines Agency Dr. Thomas Senderovitz.

The EMA’s Executive Director Professor Guido spoke about the milestones and main achievements over the past years, about the lessons derived by the EMA during 25 years, and also summed up some results of the Agency’s decades of work. The EMA was established in 1995 with a purpose to coordinate and approve the work of then existing national medicinal regulatory authorities in Europe. Over all these years, the EMA has been supporting the development of medicines and overseeing control for safety of drugs. With the passage of time, a range of issues falling under the EMA’s remit has significantly expanded. Apart from assessing the drug safety, the EMA is also responsible for products, which are developed for treating rare diseases, herbal medicines, paediatric medicines and medicinal products with a targeted therapy.

As of today, 7 scientific committees and more than 40 working groups of the EMA represent a scientific expertise on drug regulation, utilizing experience and professionalism of several thousands of European scientific experts. A joint work of the EMA with other drug regulatory authorities in the European economic zone countries, and also global experience of collaborating with the regulatory authorities, is conducive to the exchange of knowledge, ideas and development of best practices thereby ensuring the highest standards in the field of regulation of medicinal products.

The experience of one of the most major and authoritative agencies for regulation of quality of drugs is tapped by regulatory authorities from all over the world. From the Russian inspectorate’s perspective, taking part in the EMA Conference is an opportunity to receive first-hand a topical knowledge and recommendations in relation to best regulatory practices.